Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells

Experimental Cell Research

Volumn 296, Issue 2, 2004, Pages 151-162

  Whitley, Brandi R ^a   Palmieri, Diane ^a,c   Twerdi, Christine D ^a   Church, Frank C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast, ovarian, cervical, and endometrial cancer cell lines; PAI 1; Plasminogen activator inhibitors; Plasminogen activator system; Serine proteases; Serpins; Urokinase

Indexed keywords

ADENOVIRUS VECTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P14; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENE TARGETING; GENETIC TRANSFECTION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; UTERINE CERVIX CANCER; WILD TYPE;

EID: 2442545196     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.02.022     Document Type: Article

References (72)

1. Bell W.R. The fibrinolytic system in neoplasia. Semin. Thromb. Hemostasis. 22:1996;459-478
2. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:2000;25-40
3. Stefansson S., Lawrence D.A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 383:1996;441-443
4. Czekay R.P., Aertgeerts K., Curriden S.A., Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160:2003;781-791
5. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:1997;714-724
6. Ye R.D., Wun T.C., Sadler J.E. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J. Biol. Chem. 262:1987;3718-3725
7. Dickinson J.L., Bates E.J., Ferrante A., Antalis T.M. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis: evidence for an alternate biological function. J. Biol. Chem. 270:1995;27894-27904
8. Jackson T.P., Cooper S.T., Church F.C. Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor. J. Protein Chem. 16:1997;819-828
9. Schwartz B.S., Espana F. Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation. J. Biol. Chem. 274:1999;15278-15283
10. Palmieri D., Lee J.W., Juliano R.L., Church F.C. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J. Biol. Chem. 277:2002;40950-40957
11. Chambers S.K., Ivins C.M., Carcangiu M.L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer. 79:1998;449-454
12. Borgfeldt C., Hansson S.R., Gustavsson B., Masback A., Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int. J. Cancer. 92:2001;497-502
13. Konecny G., Untch M., Pihan A., Kimmig R., Gropp M., Stieber P., Hepp H., Slamon D., Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res. 7:2001;1743-1749
14. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., Astedt B. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int. J. Cancer. 79:1998;588-595
15. Hoffmann G., Pollow K., Weikel W., Strittmatter H.J., Bach J., Schaffrath M., Knapstein P., Melchert F., Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin. Chem. Lab. Med. 37:1999;47-54
16. Kuhn W., Schmalfeldt B., Reuning U., Pache L., Berger U., Ulm K., Harbeck N., Spathe K., Dettmar P., Hofler H., Janicke F., Schmitt M., Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer. 79:1999;1746-1751
17. Tecimer C., Doering D.L., Goldsmith L.J., Meyer J.S., Abdulhay G., Wittliff J.L. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int. J. Gynecol. Cancer. 10:2000;372-381
18. Tecimer C., Doering D.L., Goldsmith L.J., Meyer J.S., Abdulhay G., Wittliff J.L. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol. Oncol. 80:2001;48-55
19. Kohler U., Hiller K., Martin R., Langanke D., Naumann G., Bilek K., Janicke F., Schmitt M. Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. Gynecol. Oncol. 66:1997;268-274
20. Gleeson N.C., Gonsalves R., Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer. 72:1993;1670-1672
21. Daneri-Navarro A., Macias-Lopez G., Oceguera-Villanueva A., Del Toro-Arreola S., Bravo-Cuellar A., Perez-Montfort R., Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer. 34:1998;566-569
22. Horn L.C., Pippig S., Raptis G., Fischer U., Kohler U., Hentschel B., Martin R. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust. N. Z. J. Obstet. Gynaecol. 42:2002;383-386
23. Kobayashi H., Fujishiro S., Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 54:1994;6539-6548
24. Janicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17:1991;303-312
25. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., Lijnen H.J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer. 62:1988;531-533
26. Duffy M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin. Chem. 48:2002;1194-1197
27. Look M.P., van Putten W.L.J., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Ferno M., Eppenberger-Castori S., Sweep C.G.J.F., Ulm K., Peyrat J., Martin P., Magdelenat H., Brunner N., Duggan C., Lisboa B.W., Bendahl P., Quillien V., Daver A., Ricolleau G., Meijer-van Gelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broet P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V.A.M., Klijn J.G.M., O'Higgins N., Eppenberger U., Janicke F., Schmitt M., Foekens J.A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94:2002;116-128
28. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., Brunner N., Janicke F., Meijer-van Gelder M.E., Henzen-Logmans S.C., van Putten W.L.J., Klijn J.G.M. The urokinase system of plasminogen activation and prognosis in 780 breast cancer patients. Cancer Res. 60:2000;636-643
29. Hansen S., Overgaard J., Rose C., Knoop A., Laenkholm A.V., Andersen J., Sorensen F.B., Andreasen P.A. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br. J. Cancer. 88:2003;102-108
30. Look M., van Putten W., Duffy M., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Ferno M., Eppenberger-Castori S., Fred Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brunner N., Duggan C., Lisboa B.W., Bendah P.O., Quillien V., Daver A., Ricolleau G., Meijer-van Gelder M., Manders P., Edward Fiets W., Blankenstein M., Broet P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L., Klijn J., O'Higgins N., Eppenberger U., Janicke F., Schmitt M., Foekens J. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb. Haemostasis. 90:2003;538-548
31. Harbeck N., Kates R.E., Look M.P., Meijer-Van Gelder M.E., Klijn J.G., Kruger A., Kiechle M., Janicke F., Schmitt M., Foekens J.A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62:2002;4617-4622
32. Schneider J., Pollan M., Tejerina A., Sanchez J., Lucas A.R. Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br. J. Cancer. 88:2003;96-101
33. de Witte J.H., Sweep C.G., Klijn J.G., Grebenschikov N., Peters H.A., Look M.P., van Tienoven T.H., Heuvel J.J., Bolt-De Vries J., Benraad T.J., Foekens J.A. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br. J. Cancer. 80:1999;286-294
34. Duggan C., Kennedy S., Kramer M.D., Barnes C., Elvin P., McDermott E., O'Higgins N., Duffy M.J. Plasminogen activator inhibitor type 2 in breast cancer. Br. J. Cancer. 776:1997;622-627
35. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2509-2514
36. Liu G., Shuman M.A., Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer. 60:1995;501-506
37. Holst-Hansen C., Johannessen B., Hoyer-Hansen G., Romer J., Ellis V., Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis. 14:1996;297-307
38. Fujimoto J., Hori M., Ichigo S., Morishita S., Tamaya T. Estrogen and progestin inhibit invasiveness of gynecologic metastatic cancer cells to blood vessel endothelium. Eur. J. Gynaecol. Oncol. 19:1998;42-45
39. Arnoletti J.P., Albo D., Granick M.S., Solomon M.P., Castiglioni A., Rothman V.L., Tuszynski G.P. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer. 76:1995;998-1005
40. Farina A.R., Coppa A., Tiberio A., Tacconelli A., Turco A., Colletta G., Gulino A., Mackay A.R. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int. J. Cancer. 75:1998;721-730
41. Carriero M.V., Del Vecchio S., Capozzoli M., Franco P., Fontana L., Zannetti A., Botti G., D'Aiuto G., Salvatore M., Stoppelli M.P. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59:1999;5307-5314
42. Webb D.J., Nguyen D.H., Sankovic M., Gonias S.L. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274:1999;7412-7420
43. Nguyen D.H., Hussaini I.M., Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273:1998;8502-8507
44. Chazaud B., Ricoux R., Christov C., Plonquet A., Gherardi R.K., Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 160:2002;237-246
45. Montuori N., Mattiello A., Mancini A., Taglialatela P., Caputi M., Rossi G., Ragno P. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int. J. Cancer. 105:2003;353-360
46. Bartsch J.E., Staren E.D., Appert H.E. Matrix metalloproteinase expression in breast cancer. J. Surg. Res. 110:2003;383-392
47. Stefansson S., Lawrence D.A. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci. Signal Transduct. Knowl. Environ. 2003:2003;pe24
48. Lawrence D.A., Olson S.T., Palaniappan S., Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J. Biol. Chem. 269:1994;27657-27662
49. Lawrence D.A., Palaniappan S., Stefansson S., Olson S.T., Francis-Chmura A.M., Shore J.D., Ginsburg D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem. 272:1997;7676-7680
50. Praus M., Collen D., Gerard R.D. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int. J. Cancer. 102:2002;584-591
51. Ma D., Gerard R.D., Li X.Y., Alizadeh H., Niederkorn J.Y. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood. 90:1997;2738-2746
52. Hjortland G.O., Bjornland K., Pettersen S., Garman-Vik S.S., Emilsen E., Nesland J.M., Fodstad O., Engebraaten O. Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin. Exp. Metastasis. 20:2003;301-309
53. Praus M., Wauterickx K., Collen D., Gerard R.D. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 6:1999;227-236
54. Soff G.A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H.C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96:1995;2593-2600
55. Kjoller L., Kanse S.M., Kirkegaard T., Rodenburg K.W., Ronne E., Goodman S.L., Preissner K.T., Ossowski L., Andreasen P.A. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232:1997;420-429
56. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., Gerard R.D. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191
57. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:1998;923-928
58. Kutz S.M., Hordines J., McKeown-Longo P.J., Higgins P.J. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J. Cell Sci. 114:2001;3905-3914
59. Gleeson L.M., Chakraborty C., McKinnon T., Lala P.K. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J. Clin. Endocrinol. Metab. 86:2001;2484-2493
60. Costantini V., Sidoni A., Deveglia R., Cazzato O.A., Bellezza G., Ferri I., Bucciarelli E., Nenci G.G. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 77:1996;1079-1088
61. Bouchet C., Hacene K., Martin P.M., Becette V., Tubiana-Hulin M., Lasry S., Oglobine J., Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J. Clin. Oncol. 17:1999;3048-3057
62. Degryse B., Sier C.F., Resnati M., Conese M., Blasi F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505:2001;249-254
63. Morita Y., Hayashi Y., Kanamaru T., Itoh T., Suzuki S., Yamamoto M., Kuroda Y., Itoh H. Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells. Jpn. J. Cancer Res. 90:1999;747-752
64. Okada S.S., Grobmyer S.R., Barnathan E.S. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler., Thromb., Vasc. Biol. 16:1996;1269-1276
65. Waltz D.A., Natkin L.R., Fujita R.M., Wei Y., Chapman H.A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100:1997;58-67
66. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1996;1563-1571
67. Stefansson S., Petitclerc E., Wong M.K., McMahon G.A., Brooks P.C., Lawrence D.A. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 276:2001;8135-8141
68. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R.D., Gils A., Carmeliet G., Carmeliet P., Declerck P.J., Noel A., Foidart J.M. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16:2002;147-154
69. Isogai C., Laug W.E., Shimada H., Declerck P.J., Stins M.F., Durden D.L., Erdreich-Epstein A., DeClerck Y.A. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 61:2001;5587-5594
70. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J.M., Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152:2001;777-784
71. Kwaan H.C., Wang J., Svoboda K., Declerck P.J. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer. 82:2000;1702-1708
72. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Ploplis V.A., Castellino F.J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60:2000;5839-5847